Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2

被引：1
|
作者：
Lu, J. [1 ]
Blakely, C. M. [2 ]
Barve, M. [3 ]
Chung, C. H. [4 ]
Waqar, S. N. [5 ]
Hu, X. [6 ]
Delord, J-P. [7 ]
Krzakowski, M. J. [8 ]
Yonemori, K. [9 ]
Chen, D. T. [10 ]
Klingbiel, D. [11 ]
Heinzmann, S. [12 ]
Le Tourneau, C. [13 ]
机构：
[1] USC Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA
[2] Univ Calif San Francisco, Dept Med, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Head & Neck Endocrine Oncol, Tampa, MD USA
[5] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[6] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[7] Inst Univ Canc, Clin Res Unit, Toulouse, Haute Garonne, France
[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Lung Canc & Thorac Tumors, Warsaw, Poland
[9] Natl Canc Ctr, Dept Med Oncol, Tokyo, Japan
[10] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[11] F Hoffmann La Roche Ltd, Pharma Dev Data Sci, Data & Stat Sci, Basel, Switzerland
[12] F Hoffmann La Roche Ltd, Prod Dev & Med Affairs, Data & Stat Sci, Basel, Switzerland
[13] Paris Saclay Univ, Inst Curie, Dept Drug Dev & Innovat, Paris, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.192
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
173P
引用
收藏
页码：S204 / S205
页数：2
相关论文
共 50 条
  • [41] Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors or ROS1-Positive NSCLC with CNS Metastases
    Paz-Ares, Luis
    Dziadziuszko, Rafal
    Drilon, Alexander
    John, Thomas
    Krebs, Matthew
    Demetri, George
    Shaw, Alice T.
    Siena, Salvatore
    Wolf, Juergen
    Farago, Anna F.
    Simmons, Brian
    Pitcher, Bethany
    Huang, Xinhui
    Doebele, Robert
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 235 - 235
  • [42] Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors (vol 28, pg 1302, 2022)
    Demetri, George D.
    De Braud, Filippo
    Drilon, Alexander
    Siena, Salvatore
    Patel, Manish R.
    Cho, Byoung Chul
    Liu, Stephen, V
    Ahn, Myung-Ju
    Chiu, Chao-Hua
    Lin, Jessica J.
    Goto, Koichi
    Lee, Jeeyun
    Bazhenova, Lyudmila
    John, Thomas
    Fakih, Marwan
    Chawla, Sant P.
    Dziadziuszko, Rafal
    Seto, Takashi
    Heinzmann, Sebastian
    Pitcher, Bethany
    Chen, David
    Wilson, Timothy R.
    Rolfo, Christian
    CLINICAL CANCER RESEARCH, 2022, 28 (10) : 2196 - 2196
  • [43] Real-World Experience of NTRK Fusion-Positive Thyroid Cancer
    Park, Jong Chul
    Ashok, Arya
    Liu, Chienying
    Kang, Hyunseok
    JCO PRECISION ONCOLOGY, 2022, 6
  • [44] Clinical and analytic validation of FoundationOne CDx™ for NTRK fusion-positive solid tumors in patients treated with entrectinib
    Fabrizio, David
    Milbury, Coren
    Yip, Wai-Ki
    Yilmazel, Bahar
    Bai, Xiaobo
    Liao, Juan
    Smith, David
    Burns, Christine
    Vietz, Christine
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [45] Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
    Dziadziuszko, R.
    Siena, S.
    Tan, D. S. W.
    Cho, B. C.
    Ahn, M-J.
    Goto, K.
    Garrido-Lopez, P.
    Farago, A. F.
    Loong, H. H. F.
    Tosi, D.
    John, T.
    Wolf, J.
    Chiu, C-H.
    Liu, S. V.
    Patel, M. R.
    Drilon, A.
    Pitcher, B.
    Simmons, B.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S833 - S834
  • [46] Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp nonsmall cell lung cancer (NSCLC)
    Lu, S.
    Fan, Y.
    Chiu, C-H.
    Yu, Y.
    Loong, H. H. F.
    Lin, C-C.
    Dong, X.
    Li, J.
    Zhao, J.
    Zhang, Z.
    Zhao, N.
    Xu, T.
    Hou, M.
    Wang, D.
    Hu, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1536 - S1536
  • [47] NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy
    Marczyk, Vicente R.
    Fazeli, Sasan
    Dadu, Ramona
    Busaidy, Naifa L.
    Iyer, Priyanka
    Hu, Mimi I.
    Sherman, Steven I.
    Hamidi, Sarah
    Hosseini, Sayed Mohsen
    Williams, Michelle D.
    Ahmed, Salmaan
    Routbort, Mark J.
    Luthra, Raja
    Roy-Chowdhuri, Sinchita
    San Lucas, Francis Anthony
    Patel, Keyur P.
    Hong, David S.
    Zafereo, Mark
    Wang, Jennifer R.
    Maniakas, Anastasios
    Waguespack, Steven G.
    Cabanillas, Maria E.
    JCO PRECISION ONCOLOGY, 2025, 9
  • [48] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: of response by line of therapy
    Liu, S. V.
    De Braud, F.
    Drilon, A.
    Doebele, R. C.
    Patel, M. R.
    Cho, B. C.
    Ahn, M-J.
    Chiu, C-H.
    Farago, A. F.
    Goto, K.
    Lee, J.
    Ohe, Y.
    Ou, S-H. I.
    Cassier, P.
    Tan, D. S. W.
    Otterson, G. A.
    Veronese, L.
    Osborne, S.
    Simmons, B.
    Siena, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S472 - S473
  • [49] Entrectinib Approved for NTRK Fusion-Positive Solid Tumors and ROS1-Rearranged Non-Small Cell Lung Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 610 - 610
  • [50] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
    Doebele, Robert C.
    Drilon, Alexander
    Paz-Ares, Luis
    Siena, Salvatore
    Shaw, Alice T.
    Farago, Anna F.
    Blakely, Collin M.
    Seto, Takashi
    Cho, Byung Chul
    Tosi, Diego
    Besse, Benjamin
    Chawla, Sant P.
    Bazhenova, Lyudmila
    Krauss, John C.
    Chae, Young Kwang
    Barve, Minal
    Garrido-Laguna, Ignacio
    Liu, Stephen V.
    Conkling, Paul
    John, Thomas
    Fakih, Marwan
    Sigal, Darren
    Loong, Herbert H.
    Buchschacher, Gary L., Jr.
    Garrido, Pilar
    Nieva, Jorge
    Steuer, Conor
    Overbeck, Tobias R.
    Bowles, Daniel W.
    Fox, Elizabeth
    Riehl, Todd
    Chow-Maneval, Edna
    Simmons, Brian
    Cui, Na
    Johnson, Ann
    Eng, Susan
    Wilson, Timothy R.
    Demetri, George D.
    LANCET ONCOLOGY, 2020, 21 (02): : 271 - 282
12345